<DOC>
	<DOC>NCT00995033</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of NicVAX co-administered with varenicline as an aid in smoking cessation over a one-year period in smokers who want to quit smoking.</brief_summary>
	<brief_title>Efficacy and Safety of NicVAX® Co-administered With Varenicline (Champix®)</brief_title>
	<detailed_description />
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Varenicline</mesh_term>
	<criteria>Smokes at least 10 cigarettes per day Good general health Negative pregnancy test prior to study entry Prior exposure to NicVAX or any other nicotine vaccine Known allergic reaction to alum or any of the components of the vaccine Use of systemic steroids, immunosuppressive agents or other medication that might interfere with an immune response Cancer or cancer treatment in the last 5 years HIV infection History of drug or alcohol abuse or dependence within 12 months Significant cardiovascular, hepatic, renal, psychiatric and/or respiratory disease Previous intolerance to varenicline Inability to fulfill all visits for approximately 54 weeks</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Smoking cessation</keyword>
	<keyword>Smoking lapse behavior</keyword>
	<keyword>Smoking Relapse behavior</keyword>
	<keyword>Varenicline</keyword>
	<keyword>Nicotine conjugate vaccine</keyword>
	<keyword>Medication effect on smoking lapse behavior</keyword>
</DOC>